Reported results
- Research and development (R&D) expenses were $17.8 million for the third quarter of 2026, compared to $15.0 million for the comparable period in 2025.
- General and administrative (G&A) expenses were $3.9 million for the third quarter of 2026, compared to $4.1 million for the comparable period in 2025.
- Net loss for the third quarter of 2026 was $3.9 million, or $0.03 per basic common share, compared to a net loss of $17.5 million, or $0.21 per basic common share, for the comparable period in 2025.
- Cash, cash equivalents and short-term investments totaled $69.7 million as of September 30, 2026.
Guidance
- The Company expects cash, cash equivalents and short-term investments currently on hand to fund operations into Q2 2027.
- Initiate global Phase 3 LEGACY trial of tegoprubart in kidney transplantation in the fourth quarter of 2026.
- Initiate a Company-sponsored, registrational path study evaluating tegoprubart in T1D patients undergoing islet cell transplantation.
- Initiate an investigator-led study evaluating tegoprubart for the prevention of organ rejection in patients receiving a de novo liver transplant.
- Receive FDA regulatory guidance on the path to market for tegoprubart in kidney xenotransplantation.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.
